Andrew Zelenetz, MD, PhD, discusses the dual strategy of using the duration of benefit metric and re-biopsy to navigate complex sequencing decisions in targeted lymphoma therapy.
Guidelines | NCCN Guideline Update for Follicular Lymphoma: Translating NCCN Updates Into Follicular Lymphoma Practice
NCCN Guideline Update for Follicular Lymphoma: Translating NCCN Updates Into Follicular Lymphoma Practice
Videos
The NCCN guidance transitioned from a specific focus on rituximab to a broad, future-proof policy covering all FDA-approved biosimilars, which simplifies treatment decisions and promotes patient access.
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
3
ACA Subsidy Expiration Raises Concerns for Behavioral Health Access and ED Strain
4
HIV in 2025 Defined by Challenges Throughout the Year, Despite Some Advances
5
